Safety and Tolerability

  • PEA appears to be well tolerated*
  • Meta-analysis suggested that all-cause dropout was reduced but not to a significant degree in the PEA group compared to inactive control conditions (RR =0.36, 95% CI: 0.10 – 1.26, z = -1.60, P = 0.11).
  • The all-cause dropout rate was 1.1% with PEA treatment (14 out of 1,269 patients) compared to 4.3% (32 out of 738 patients) in the inactive control groups.
  • Adverse events reported with PEA treatment in previous trials included
  • Gastrointestinal upset
  • Drowsiness
  • Heart palpitations

*Br J Clin Pharmacol (2016) 82 932–942
Pain Physician 2017; 20:353-362